ClinicalTrials.gg
CompletedNCT06996483TRACE-GIUpdated Nov 13, 2026

Sleep Disturbance, Depressive Symptoms, and Subsequent Quality of Life During Adjuvant Chemotherapy for Gastrointestinal Cancer

An observational study in Gastrointestinal Neoplasms, sponsored by Ankara Etlik City Hospital. Completed at 3 sites in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Ankara Etlik City Hospital · Observational

How we know

Updated Nov 13, 2026Primary completion movedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
198
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Gastrointestinal Neoplasms with a site in Turkey — 3 open to participants now, 5 under way, 1 of them phase 3. Gastrointestinal Neoplasms · Turkey.

Enrollment
2nd of 13
198 · median 100
Started
2025
with 3 others
Observational
13 of 21
2 open now
Registered
13th of 21
by date
Lead sponsor
3 of 21
Ankara Etlik City Hospital

Among the 21 studies in Gastrointestinal Neoplasms with a site in Turkey, this one is the 2nd largest by enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, and was the 13th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

3 of the 21 studies in Gastrointestinal Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Gastrointestinal Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, single-center, non-interventional observational cohort study evaluated longitudinal changes in sleep quality, depressive symptoms, and health-related quality of life among adults receiving fluoropyrimidine-based adjuvant chemotherapy for nonmetastatic gastrointestinal cancers.

A total of 198 participants receiving either FOLFOX or CAPEOX were enrolled at Ankara Etlik City Hospital between May 30, 2025, and March 30, 2026. Longitudinal patient-reported outcomes included the Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

The longitudinal assessment framework included baseline, month-3, and month-6 evaluations. In addition to describing changes in sleep, depressive symptoms, and quality of life, analyses examined the temporal indirect association between baseline sleep disturbance and month-6 global health status/quality of life through month-3 depressive symptoms.

Secondary analyses evaluated nutritional status, anthropometric measures, and body composition using clinically available computed tomography examinations. Treatment-regimen comparisons were observational and did not involve investigator-directed treatment assignment.

The final follow-up data cutoff was September 30, 2026.

Read the detailed description

This prospective, single-center observational study was conducted in the Medical Oncology Department of Ankara Etlik City Hospital, Türkiye, among adults with histologically confirmed nonmetastatic gastrointestinal malignancies who were scheduled to receive fluoropyrimidine-based adjuvant chemotherapy.

Participants received standard-of-care treatment with either FOLFOX, an intravenous fluorouracil-based regimen, or CAPEOX, an oral capecitabine-based regimen combined with intravenous oxaliplatin. Treatment allocation was determined by routine clinical care rather than research assignment.

The final cohort comprised 198 participants. Recruitment began on May 30, 2025, and ended on March 30, 2026. The longitudinal assessment schedule included baseline, month 3, and month 6, with a final follow-up data cutoff of September 30, 2026.

Sleep quality was evaluated using the PSQI, depressive symptoms using the BDI, and health-related quality of life using the EORTC QLQ-C30. The principal quality-of-life domains evaluated included global health status/quality of life, physical functioning, and fatigue.

Longitudinal analyses characterized changes in patient-reported outcomes during adjuvant chemotherapy. A longitudinal path model examined the association between baseline PSQI and month-6 global health status/quality of life through month-3 depressive symptom burden. The reciprocal temporal association was also evaluated. These models were interpreted as observational associations rather than evidence of causal mediation.

Additional analyses evaluated the relationships of baseline and longitudinal body-composition measurements with subsequent health-related quality of life. Skeletal muscle index and muscle attenuation were obtained from routine clinically available computed tomography examinations; no additional CT examinations were required solely for research purposes.

Nutritional screening, body weight, body mass index, treatment-related factors, and relevant baseline clinical characteristics were recorded. Exploratory analyses examined longitudinal differences according to chemotherapy regimen.

The study did not modify standard oncological treatment. Patients requiring additional assessment for clinically significant sleep disturbances or psychological symptoms could be referred for appropriate clinical evaluation.

The original ClinicalTrials.gov registration emphasized comparisons of oral versus intravenous fluoropyrimidine-based regimens and early PSQI/BDI assessments. Subsequent registration updates should be interpreted in conjunction with the dated ethics-approved study protocol, the actual longitudinal assessment schedule, and the publicly available registration history.

03

Conditions studied

  • Gastrointestinal Neoplasms

Keywords

  • Adjuvant Chemotherapy
  • 5-Fluorouracil
  • Sleep Quality
  • Depression
  • Gastrointestinal Cancer
  • Oral Chemotherapy
  • Intravenous Chemotherapy
  • Beck Depression Inventory
  • Pittsburgh Sleep Quality Index
  • sarcopenia
  • skeletal muscle index
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprised 198 consecutive adult patients with histologically confirmed stage II-III gastric or colorectal cancer receiving standard-of-care adjuvant FOLFOX (n=102) or CAPEOX (n=96) at Ankara Etlik City Hospital, Türkiye. Participants were prospectively enrolled between May 30, 2025, and March 30, 2026. Sleep quality, depressive symptoms, and health-related quality of life were assessed at baseline, month 3, and month 6. Nutritional and anthropometric measures were recorded, and body composition was evaluated using available routine CT examinations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • confirmed nonmetastatic gastric, colon, or rectal cancer.
  • Pathologic stage II or III disease.
  • Planned initiation of fluoropyrimidine-based chemotherapy with FOLFOX or CAPEOX.
  • (ECOG) performance status of 0-2.
  • Ability to understand and complete the Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and EORTC QLQ-C30 questionnaires.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • (stage IV) gastrointestinal cancer.
  • Regular pharmacological treatment specifically prescribed for insomnia or primary sleep disorders at baseline.
  • Psychiatric, neurological, or cognitive conditions that preclude reliable completion of patient-reported outcome questionnaires.
  • Inability to complete study assessments because of language or communication barriers.
  • Inability to participate in the scheduled longitudinal follow-up assessments.

Pre-existing selective serotonin reuptake inhibitor (SSRI) therapy was not considered an exclusion criterion solely on the basis of medication class. Baseline SSRI use was documented and accounted for in the statistical analyses.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
198 participants (actual)
Patient registry
No

Groups and cohorts

  • CAPEOX Cohort

    Patients with nonmetastatic gastrointestinal cancer receiving standard-of-care adjuvant chemotherapy with CAPEOX (oral capecitabine plus intravenous oxaliplatin). This observational cohort comprised 96 participants. Treatment selection was determined by routine clinical practice, without investigator-directed treatment assignment.

  • FOLFOX Cohort

    Patients with nonmetastatic gastrointestinal cancer receiving standard-of-care adjuvant chemotherapy with FOLFOX (intravenous fluorouracil, leucovorin, and oxaliplatin). This observational cohort comprised 102 participants. Treatment selection was determined by routine clinical practice, without investigator-directed treatment assignment.

06

What researchers measure

Primary outcomes

  1. Longitudinal Indirect Association Between Sleep Disturbance, Depressive Symptoms, and Quality of Life

    The indirect association of baseline Pittsburgh Sleep Quality Index (PSQI) score with month-6 EORTC QLQ-C30 global health status/quality-of-life score through month-3 Beck Depression Inventory (BDI) score is estimated using an adjusted longitudinal path model. The indirect association is expressed as the product of regression coefficients (a×b), with a bootstrap 95% confidence interval.

    Time frame: Baseline, Month 3, and Month 6 (up to 6 months after chemotherapy initiation).

Secondary outcomes

  1. Longitudinal Change in Depressive Symptoms Assessed by the Beck Depression Inventory

    Depressive symptoms are assessed using the Beck Depression Inventory (BDI), with total scores ranging from 0 to 63. Higher scores indicate greater depressive symptom burden. Changes in BDI total scores are evaluated across baseline, month 3, and month 6 using longitudinal mixed-effects models.

    Time frame: Baseline, Month 3, and Month 6.

  2. Longitudinal Change in EORTC QLQ-C30 Global Health Status/Quality of Life

    Global health status/quality of life is assessed using the EORTC QLQ-C30 global health status scale, ranging from 0 to 100. Higher scores indicate better quality of life. Changes over time are evaluated using longitudinal mixed-effects models.

    Time frame: Baseline, Month 3, and Month 6.

  3. Longitudinal Changes in Physical Functioning and Fatigue

    Physical functioning and fatigue are evaluated using the corresponding EORTC QLQ-C30 scales (0-100). Higher physical-functioning scores represent better functioning, whereas higher fatigue scores indicate greater symptom burden. Longitudinal changes are assessed across three scheduled visits.

    Time frame: Baseline, Month 3, and Month 6.

  4. Longitudinal Change in Skeletal Muscle Index (SMI)

    Skeletal muscle index (SMI, cm²/m²) is calculated from skeletal muscle cross-sectional area at the third lumbar vertebral level (L3), measured using clinically available computed tomography (CT) images and normalized to height squared. Longitudinal changes in SMI and its associations with month-6 health-related quality of life are evaluated. No additional CT scans are performed for research purposes.

    Time frame: Baseline, Month 3, and Month 6 (when routine CT images are available).

  5. Longitudinal Change in Skeletal Muscle Attenuation

    Skeletal muscle attenuation is measured in Hounsfield units (HU) from L3 skeletal muscle segmentation on routine CT images. Longitudinal changes in muscle attenuation and its associations with month-6 global health status/quality of life, physical functioning, and fatigue are evaluated. Higher attenuation generally indicates lower intramuscular fat content.

    Time frame: Baseline, Month 3, and Month 6 (when routine CT images are available).

07

Study locations

3 sites
  • Ankara Etlik City Hospital
    Ankara, Yenimahalle 06210, Turkey (Türkiye)
  • Etlik City Hospital, Medical Oncology Department
    Ankara, Yenimahalle 06210, Turkey (Türkiye)
  • Etlik City Hospital
    Ankara, Yenimahalle 06210, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to local data protection regulations, ethical restrictions, and the absence of prior consent for data sharing.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Apr 2026, 10 months.

Of 79 non-industry observational studies under Gastrointestinal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 14. This study's 10 months is below that.

Counting every sponsor, half of 88 studies reached it within 43 months; a quarter within 16 and three quarters within 102.

Start moved once since we started tracking on Sep 25, 2026: Jun 2025 → May 2025, on Oct 13, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Oct 2025 → Apr 2026, last on Nov 13, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
May 30, 2025was Jun 2025
Primary completionActual
Apr 14, 2026was Oct 2025
CompletionActual
Sep 30, 2026was Apr 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 5, 2025→May 30, 2025
Oct 13, 2026
Primary completion
Oct 5, 2025→Apr 14, 2026
moved 2 times, Oct 13, 2026 – Nov 13, 2026
Study completion
Apr 26, 2026→Sep 30, 2026
Oct 13, 2026
Eligibility
Criteria largely rewritten (21 changes)
What changed in the criteria
Inclusion criteria
  • RemovedHistopathologically confirmed non-metastatic gastrointestinal system cancer (e.g., colorectal, gastric)
  • RemovedAge ≥18 years
  • RemovedPlanned to receive adjuvant chemotherapy containing 5-FU (either oral or IV)
  • AddedAdults aged 18 years or older.
  • AddedHistologically confirmed nonmetastatic gastric, colon, or rectal cancer.
  • AddedPathologic stage II or III disease.
  • AddedPlanned initiation of fluoropyrimidine-based adjuvant chemotherapy with FOLFOX or CAPEOX.
  • EditedEastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • RemovedProvided informed consent
  • AddedAbility to understand and complete the Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and EORTC QLQ-C30 questionnaires.
  • AddedProvision of written informed consent.
Exclusion criteria
  • RemovedPatients with psychiatric disorders affecting sleep or mood
  • RemovedReceiving treatment for primary sleep disorders or depression
  • RemovedPrior chemotherapy or radiotherapy for the current diagnosis
  • RemovedInability to complete the questionnaires due to cognitive or language barriers
  • AddedMetastatic (stage IV) gastrointestinal cancer.
  • AddedRegular pharmacological treatment specifically prescribed for insomnia or primary sleep disorders at baseline.
  • AddedPsychiatric, neurological, or cognitive conditions that preclude reliable completion of patient-reported outcome questionnaires.
  • AddedInability to complete study assessments because of language or communication barriers.
  • AddedInability to participate in the scheduled longitudinal follow-up assessments.
  • AddedPre-existing selective serotonin reuptake inhibitor (SSRI) therapy was not considered an exclusion criterion solely on the basis of medication class. Baseline SSRI use was documented and accounted for in the statistical analyses.
Oct 13, 2026
Interventions
Arms added: CAPEOX Cohort·FOLFOX Cohort; arms removed: Oral 5-FU Group·Intravenous 5-FU Group
Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in Sleep Quality Score (Pittsburgh Sleep Quality Index - PSQI)Now Longitudinal Indirect Association Between Sleep Disturbance, Depressive Symptoms, and Quality of LifeTime frame: Baseline, Day 45, Day 90 → Baseline, Month 3, and Month 6 (up to 6 months after chemotherapy initiation).
Oct 13, 2026
Secondary outcomes
5 added, 1 removed
What changed in the outcomes
  • AddedLongitudinal Change in Depressive Symptoms Assessed by the Beck Depression InventoryTime frame: Baseline, Month 3, and Month 6.
  • AddedLongitudinal Change in EORTC QLQ-C30 Global Health Status/Quality of LifeTime frame: Baseline, Month 3, and Month 6.
  • AddedLongitudinal Changes in Physical Functioning and FatigueTime frame: Baseline, Month 3, and Month 6.
  • AddedLongitudinal Change in Skeletal Muscle Index (SMI)Time frame: Baseline, Month 3, and Month 6 (when routine CT images are available).
  • AddedLongitudinal Change in Skeletal Muscle AttenuationTime frame: Baseline, Month 3, and Month 6 (when routine CT images are available).
  • RemovedChange in Depression Score (Beck Depression Inventory - BDI)Time frame: Baseline, Day 45, Day 90
Oct 13, 2026
Title
Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers→Sleep Disturbance, Depressive Symptoms, and Subsequent Quality of Life During Adjuvant Chemotherapy for Gastrointestinal Cancer
Oct 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Primary completion Mar 30, 2026→Apr 14, 2026
  2. Oct 13, 2026
    Start date Jun 5, 2025→May 30, 2025
    Primary completion Oct 5, 2025→Mar 30, 2026
    Study completion Apr 26, 2026→Sep 30, 2026
    Eligibility Criteria largely rewritten (21 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedHistopathologically confirmed non-metastatic gastrointestinal system cancer (e.g., colorectal, gastric)
    • RemovedAge ≥18 years
    • RemovedPlanned to receive adjuvant chemotherapy containing 5-FU (either oral or IV)
    • AddedAdults aged 18 years or older.
    • AddedHistologically confirmed nonmetastatic gastric, colon, or rectal cancer.
    • AddedPathologic stage II or III disease.
    • AddedPlanned initiation of fluoropyrimidine-based adjuvant chemotherapy with FOLFOX or CAPEOX.
    • EditedEastern Cooperative Oncology Group (ECOG) performance status of 0-2.
    • RemovedProvided informed consent
    • AddedAbility to understand and complete the Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and EORTC QLQ-C30 questionnaires.
    • AddedProvision of written informed consent.
    Exclusion criteria
    • RemovedPatients with psychiatric disorders affecting sleep or mood
    • RemovedReceiving treatment for primary sleep disorders or depression
    • RemovedPrior chemotherapy or radiotherapy for the current diagnosis
    • RemovedInability to complete the questionnaires due to cognitive or language barriers
    • AddedMetastatic (stage IV) gastrointestinal cancer.
    • AddedRegular pharmacological treatment specifically prescribed for insomnia or primary sleep disorders at baseline.
    • AddedPsychiatric, neurological, or cognitive conditions that preclude reliable completion of patient-reported outcome questionnaires.
    • AddedInability to complete study assessments because of language or communication barriers.
    • AddedInability to participate in the scheduled longitudinal follow-up assessments.
    • AddedPre-existing selective serotonin reuptake inhibitor (SSRI) therapy was not considered an exclusion criterion solely on the basis of medication class. Baseline SSRI use was documented and accounted for in the statistical analyses.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in Sleep Quality Score (Pittsburgh Sleep Quality Index - PSQI)Now Longitudinal Indirect Association Between Sleep Disturbance, Depressive Symptoms, and Quality of LifeTime frame: Baseline, Day 45, Day 90 → Baseline, Month 3, and Month 6 (up to 6 months after chemotherapy initiation).
    Secondary outcomes 5 added, 1 removed
    What changed in the outcomes
    • AddedLongitudinal Change in Depressive Symptoms Assessed by the Beck Depression InventoryTime frame: Baseline, Month 3, and Month 6.
    • AddedLongitudinal Change in EORTC QLQ-C30 Global Health Status/Quality of LifeTime frame: Baseline, Month 3, and Month 6.
    • AddedLongitudinal Changes in Physical Functioning and FatigueTime frame: Baseline, Month 3, and Month 6.
    • AddedLongitudinal Change in Skeletal Muscle Index (SMI)Time frame: Baseline, Month 3, and Month 6 (when routine CT images are available).
    • AddedLongitudinal Change in Skeletal Muscle AttenuationTime frame: Baseline, Month 3, and Month 6 (when routine CT images are available).
    • RemovedChange in Depression Score (Beck Depression Inventory - BDI)Time frame: Baseline, Day 45, Day 90
    Interventions Arms added: CAPEOX Cohort·FOLFOX Cohort; arms removed: Oral 5-FU Group·Intravenous 5-FU Group
    Title Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers→Sleep Disturbance, Depressive Symptoms, and Subsequent Quality of Life During Adjuvant Chemotherapy for Gastrointestinal Cancer
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06996483
Responsible party
Galip Can Uyar (Medical Oncology, MD, Ankara Etlik City Hospital) — Principal investigator
First posted
May 30, 2025
Start date
May 30, 2025
Primary completion
Apr 14, 2026
Completion
Sep 30, 2026
Last update
Nov 13, 2026

Study contacts

Dr. Osman Sütcüoğlu, MD
study director · Etlik City Hospital, Medical Oncology Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion